J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC
Johnson & Johnson announced Tuesday that the FDA has approved Rybrevant with Lazcluze as a first-line chemotherapy-free treatment for patients with EGFR-mutated non-small cell lung cancer.
J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC Read More »
